IL151087A0 - Protease inhibitors - Google Patents
Protease inhibitorsInfo
- Publication number
- IL151087A0 IL151087A0 IL15108701A IL15108701A IL151087A0 IL 151087 A0 IL151087 A0 IL 151087A0 IL 15108701 A IL15108701 A IL 15108701A IL 15108701 A IL15108701 A IL 15108701A IL 151087 A0 IL151087 A0 IL 151087A0
- Authority
- IL
- Israel
- Prior art keywords
- protease inhibitors
- protease
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D421/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19849300P | 2000-04-18 | 2000-04-18 | |
US27381101P | 2001-03-07 | 2001-03-07 | |
PCT/US2001/012326 WO2001089451A2 (en) | 2000-04-18 | 2001-04-17 | Protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151087A0 true IL151087A0 (en) | 2003-04-10 |
Family
ID=26893840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15108701A IL151087A0 (en) | 2000-04-18 | 2001-04-17 | Protease inhibitors |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1278502A4 (en) |
JP (1) | JP2004526662A (en) |
KR (1) | KR20020089482A (en) |
CN (1) | CN1431904A (en) |
AR (1) | AR032319A1 (en) |
AU (1) | AU9050701A (en) |
BR (1) | BR0108954A (en) |
CA (1) | CA2406829A1 (en) |
CO (1) | CO5280088A1 (en) |
CZ (1) | CZ20023460A3 (en) |
HK (1) | HK1053785A1 (en) |
HU (1) | HUP0301781A2 (en) |
IL (1) | IL151087A0 (en) |
MX (1) | MXPA02010276A (en) |
NO (1) | NO20025005L (en) |
PL (1) | PL366040A1 (en) |
WO (1) | WO2001089451A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004527575A (en) * | 2001-05-17 | 2004-09-09 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
US20050030912A1 (en) * | 2002-08-22 | 2005-02-10 | Enikia L.L.C. | Use of hybrid (HW/DSP/MCU/SW) architectures for powerline OFDM communication field |
WO2004028521A2 (en) | 2002-09-24 | 2004-04-08 | Novartis Ag | Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
JP2006504719A (en) * | 2002-10-08 | 2006-02-09 | メルク フロスト カナダ アンド カンパニー | 4-Amino-azepan-3-one compounds as cathepsin K inhibitors useful in the treatment of osteoporosis |
US7297714B2 (en) * | 2003-10-21 | 2007-11-20 | Irm Llc | Inhibitors of cathepsin S |
GB2449601B (en) * | 2006-02-21 | 2010-06-23 | Agency Science Tech & Res | Method and reagents for treating hepatic fibrosis and inflammation |
EP2216047A4 (en) * | 2007-10-24 | 2011-12-28 | Nat Univ Corp Tokyo Med & Dent | Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
KR20160131126A (en) | 2008-06-20 | 2016-11-15 | 노파르티스 아게 | Paediatric compositions for treating multiple sclerosis |
LV15485B (en) * | 2018-09-13 | 2020-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenophene chromenone hydroxamic acids, their production and use in angiogenesis inhibition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518528A (en) * | 1983-05-19 | 1985-05-21 | Rasnick David W | α Amino fluoro ketones |
CA2122227A1 (en) * | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
DZ2285A1 (en) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Cysteine protease inhibitors. |
HUP0104768A3 (en) * | 1998-12-23 | 2002-05-28 | Smithkline Beecham Corp | 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same |
US7071184B2 (en) * | 2000-03-21 | 2006-07-04 | Smithkline Beecham Corporation | Protease inhibitors |
EP1320370A4 (en) * | 2000-09-01 | 2008-10-22 | Smithkline Beecham Corp | Method of treatment |
-
2001
- 2001-04-16 CO CO01029287A patent/CO5280088A1/en not_active Application Discontinuation
- 2001-04-17 JP JP2001585697A patent/JP2004526662A/en not_active Withdrawn
- 2001-04-17 CA CA002406829A patent/CA2406829A1/en not_active Abandoned
- 2001-04-17 BR BRPI0108954-4A patent/BR0108954A/en not_active IP Right Cessation
- 2001-04-17 WO PCT/US2001/012326 patent/WO2001089451A2/en not_active Application Discontinuation
- 2001-04-17 AU AU90507/01A patent/AU9050701A/en not_active Abandoned
- 2001-04-17 MX MXPA02010276A patent/MXPA02010276A/en unknown
- 2001-04-17 AR ARP010101786A patent/AR032319A1/en not_active Application Discontinuation
- 2001-04-17 KR KR1020027013896A patent/KR20020089482A/en not_active Application Discontinuation
- 2001-04-17 CZ CZ20023460A patent/CZ20023460A3/en unknown
- 2001-04-17 HU HU0301781A patent/HUP0301781A2/en unknown
- 2001-04-17 IL IL15108701A patent/IL151087A0/en unknown
- 2001-04-17 CN CN01808290A patent/CN1431904A/en active Pending
- 2001-04-17 EP EP01970508A patent/EP1278502A4/en not_active Withdrawn
- 2001-04-17 PL PL01366040A patent/PL366040A1/en not_active Application Discontinuation
-
2002
- 2002-10-17 NO NO20025005A patent/NO20025005L/en not_active Application Discontinuation
-
2003
- 2003-06-19 HK HK03104420.9A patent/HK1053785A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0301781A2 (en) | 2003-09-29 |
BR0108954A (en) | 2006-05-09 |
MXPA02010276A (en) | 2003-04-25 |
NO20025005L (en) | 2002-12-06 |
JP2004526662A (en) | 2004-09-02 |
WO2001089451A3 (en) | 2002-04-04 |
CN1431904A (en) | 2003-07-23 |
AR032319A1 (en) | 2003-11-05 |
HK1053785A1 (en) | 2003-11-07 |
PL366040A1 (en) | 2005-01-24 |
KR20020089482A (en) | 2002-11-29 |
WO2001089451A2 (en) | 2001-11-29 |
CO5280088A1 (en) | 2003-05-30 |
CA2406829A1 (en) | 2001-11-29 |
EP1278502A2 (en) | 2003-01-29 |
NO20025005D0 (en) | 2002-10-17 |
CZ20023460A3 (en) | 2004-03-17 |
AU9050701A (en) | 2001-12-03 |
EP1278502A4 (en) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2002002593A0 (en) | Protease inhibitors | |
GB0125445D0 (en) | Protease Inhibitors | |
IL215892A0 (en) | Peptidomimetic protease inhibitors | |
IL153421A0 (en) | Protease inhibitors | |
EP1235577A4 (en) | Protease inhibitors | |
EP1232155A4 (en) | Protease inhibitors | |
IL151087A0 (en) | Protease inhibitors | |
EP1231921A4 (en) | Protease inhibitors | |
EP1229912A4 (en) | Protease inhibitors | |
EP1229914A4 (en) | Protease inhibitors | |
EP1229915A4 (en) | Protease inhibitors | |
EP1173429A4 (en) | Protease inhibitors | |
EP1233771A4 (en) | Protease inhibitors | |
EP1229911A4 (en) | Protease inhibitors | |
EP1351930A4 (en) | Protease inhibitors | |
HK1043534A1 (en) | Protease inhibitors | |
EP1401453A4 (en) | Protease inhibitors | |
EP1231923A4 (en) | Protease inhibitors | |
IL155997A0 (en) | Protease inhibitors | |
IL155961A0 (en) | Cysteine protease inhibitors | |
EP1232154A4 (en) | Protease inhibitors | |
EP1231922A4 (en) | Protease inhibitors | |
AU6407701A (en) | Serine protease inhibitors | |
GB0009123D0 (en) | Protease inhibitor | |
ZA200207478B (en) | Protease inhibitors. |